

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF NEW YORK**

NOVARTIS PHARMA AG, NOVARTIS
PHARMACEUTICALS CORPORATION, and
NOVARTIS TECHNOLOGY LLC,

Plaintiffs,

v.

REGENERON PHARMACEUTICALS, INC.,

Defendant.

Civil Action No. 1:20-cv-00690 (DNH-
CFH)

STIPULATION AND [PROPOSED] ORDER MODIFYING CASE SCHEDULE

WHEREAS, Plaintiffs Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation (collectively, “Plaintiffs”) and Defendant Regeneron Pharmaceuticals, Inc. (“Defendant”) (Plaintiffs and Defendant, collectively, “Parties”) have been engaged in discovery in the above-captioned action,

WHEREAS, Plaintiffs’ damages expert report served on July 7, 2022 relied on several third-party license agreements;

WHEREAS, the Parties have met and conferred and agreed to seek an extension of deadlines for discovery for purposes of accommodating targeted third-party discovery concerning these agreements;

IT IS NOW, THEREFORE, HEREBY STIPULATED AND AGREED, by and between the Parties, through their undersigned attorneys and subject to the Court’s approval, that:

1. The current case schedule (NDNY ECF No. 125) is hereby modified as follows:

EVENT	CURRENT DATE	AMENDED DATE
Deadline for completion of third-party discovery concerning license agreements to be completed as expeditiously as possible	N/A	October 14, 2022
Plaintiffs' Supplemental Expert Reports Limited to third-party discovery concerning license agreements (if any)	N/A	October 21, 2022
Responsive Expert Reports	August 4, 2022	November 8, 2022
Close of Discovery	August 19, 2022	December 2, 2022
Opening Dispositive Motions	September 1, 2022	December 16, 2022
Responses to Dispositive Motions	September 21, 2022	January 10, 2023
Replies to Dispositive Motions	September 29, 2022	January 20, 2023

2. Regeneron expects to serve third party subpoenas by July 29, 2022 and the parties will meet and confer should Regeneron seek to serve further subpoenas.

3. If third party discovery is completed in advance of October 14, 2022, the parties will meet and confer regarding acceleration of subsequent dates in the schedule.

4. The above-modified dates do not affect the deadlines set forth in the Amended Expert Discovery Schedule for Willful Infringement and Inequitable Conduct (D.I. 139).

STIPULATED TO AND APPROVED BY:

Dated: July 27, 2022

/s/ Elizabeth Holland

Elizabeth Holland
ALLEN & OVERY LLP
1221 Avenue of the Americas
New York, New York 10020
Telephone: (212) 610 6365
Facsimile: (212) 610 6399
Elizabeth.Holland@allenoverly.com

George R. McGuire (Bar Roll No. 509058)
Louis Orbach (Bar Roll No. 507815)
BOND, SCHOENECK & KING, PLLC
ONE Lincoln Center
Syracuse, NY 13202
Phone (315) 218-8000
Fax (315) 218-8100

*Counsel for Plaintiffs Novartis Pharma
AG, Novartis Technology LLC, and
Novartis Pharmaceuticals Corp.*

/s/ Elizabeth Weiswasser

Elizabeth Stotland Weiswasser (Bar Roll No. 701918)
Anish R. Desai (Bar Roll No. 701945)
WEIL, GOTSHAL & MANGES LLP
767 Fifth Avenue
New York, New York 10153-0119 Telephone: (212) 310-8000
Fax: (212) 310-8007
elizabeth.weiswasser@weil.com
anish.desai@weil.com

Douglas J. Nash (Bar Roll No. 511889)
John D. Cook (Bar Roll No. 511491)
BARCLAY DAMON LLP
Barclay Damon Tower
125 East Jefferson Street
Syracuse, New York 13202

Telephone: (315) 425-2885
dnash@barclaydamon.com
jcook@barclaydamon.com

*Counsel for Defendant Regeneron
Pharmaceuticals, Inc.*

ORDER

IT IS SO ORDERED this _____ day of, _____ 2022.

Hon. Christian F. Hummel